Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy

Adverse Drug Reaction Bulletin

Volumn , Issue 260, 2010, Pages 999-1002

  Pane, P ^a   Arcieri, R ^a   Bonati, M ^b   Bugarini, M ^a   Didoni, A ^b   Germinario, E ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; ALOPECIA; APHASIA; APPETITE; ARTICLE; ASTHENIA; ATTENTION DEFICIT DISORDER; BLADDER DISEASE; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERNATREMIA; HYPERTENSION; HYPOMANIA; HYPOTENSION; IMPOTENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MICTURITION DISORDER; NEUROLOGIC DISEASE; PERSONALITY DISORDER; PRESCHOOL CHILD; PRESCRIPTION; PROTEINURIA; QT PROLONGATION; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SUICIDAL IDEATION; TACHYCARDIA; THROMBOCYTOPOIESIS; TIC; URTICARIA;

EID: 77749245834     PISSN: 00446394     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. American Academy of Pediatrics. Clinical practice guidelines: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105:1158-1170.
2. Coghill D, Soutullo C, d'Aubuisson C, et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child and Adolescent Psychiatry and Mental Health 2008;2:31.
3. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archivés of General Psychiatry 1999;56:1073-1086
4. Molina BSG, Hinshaw SP, Swanson JM, et al., The MTA Cooperative GroupMTA at 8 Years: prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry 2009;48:5.
5. Greene RW, Biederman J, Faraone SV, et al. Toward a new psychometric definition of social disability in children with attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1996;35:571-578.
6. Stein MA, Szumowski E, Blondis TA, Roizen NJ. Adaptive skills dysfunction in ADD and ADHD children. Journal of Child Psychology and Psychiatry, and Allied Disciplines 1995;36:663-670.
7. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. Journal of the American Academy of Child and Adolescent Psychiatry 1990;29:546-557.
8. Biederman J, Mick E, Faraone SV. Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder. The Journal of Pediatrics 1998;133:544-551.
9. Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ: Canadian Medical Association Journal 2001;165:1475-1488.
10. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107:E105.
11. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Archives of General Psychiatry 2003;60:204-211.
12. Favreau A, Deseille-Turlotte G, Brault F, et al. Benefit of the extended-release methylphenidate formulations: a comparative study in childhood [in French]. Archives of Pediatrics 2006;13:442-448.
13. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatric Drugs 2003;5:833-841.
14. Prasad S, Steer C. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: clinical approaches and review of current available evidence. Paediatric Drugs 2008;10:39-47.
15. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008;121:e314-e320.
16. Bakken RJ, Paczkowski M, Kramer HP, et al. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. Current Medical Research and Opinion 2008;24:449-460.
17. Greenhill LL, Vitiello BB, Riddle MA, et al. Review of safety assessment methods used in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry 2003;42:627-633.
18. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Archives of Disease in Childhood 2005;90:801-806.
19. Panei P, Knellwolf AL, Arcieri R, Vella S. Absence of unfavorable effect of atomoxetine on growth in pediatric patients is still not demonstrated. Pediatrics 2006; 117:587-588.
20. Pocock N. FDA panel to review cardiac safety of ADHD medication. Reuters Health; 2006.
21. New warning about ADHD drug. FDA Consumer 2005;39:3.
22. FDA Drug Safety warning; June 2009. http://www.fda.gov/Drugs/DrugSafety/ DrugSafetyNewsletter/ucml 10235.htm. http://www.fda.gov/Safety/MedWatch/Safety Information/ucml53825.htm.
23. Panei P, Arcieri R, Vella S, et al. Italian Attention-Deficit/ Hyperactivity Disorder Registry. Pediatrics 2004;114:514.
24. Medicines and Healthcare Products Regulatory Agency Drug Analysis printout for atomoxetine. 2010. http://www.mhra.gov.uk/Onlineservices/Medicines/ Druganalysisprints/DAP-1264169380595. [Accessed 28 January 2010]
25. Medicines and Healthcare Products Regulatory Agency Drug Analysis printout for methylphenidate. 2010. http://www.mhra.gov.uk/Onlineservices/ Medicines/Druganalysisprints/DAPJ 264176482031. [Accessed 28 January 2010]